Literature DB >> 7066061

Weekly intravenous methotrexate in the treatment of rheumatoid arthritis.

R M Michaels, D J Nashel, A Leonard, A J Sliwinski, S J Derbes.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7066061     DOI: 10.1002/art.1780250312

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


× No keyword cloud information.
  7 in total

Review 1.  Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis.

Authors:  M Cutolo; A Sulli; C Pizzorni; B Seriolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2001-08       Impact factor: 19.103

2.  In rheumatoid arthritis is compliance in physicians more of a problem than compliance in patients?

Authors:  R J Rooney; W W Buchanan
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

3.  Methotrexate therapy in rheumatoid arthritis. Current status.

Authors:  W S Wilke; A H Mackenzie
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

Review 4.  Hepatotoxicity of methotrexate in rheumatic diseases.

Authors:  S Kevat; M Ahern; P Hall
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

5.  Low-dose methotrexate treatment of rheumatoid arthritis; long-term observation of efficacy and safety.

Authors:  E Szanto
Journal:  Clin Rheumatol       Date:  1989-09       Impact factor: 2.980

6.  Prospidine versus methotrexate pulse in highly active rheumatoid arthritis: a controlled 6-month clinical trial.

Authors:  E V Benenson; O B Timina
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

7.  Low dose pulse methotrexate in rheumatoid arthritis: an 8-year experience with hepatotoxicity.

Authors:  P A Leonard; D O Clegg; C C Carson; G W Cannon; M J Egger; J R Ward
Journal:  Clin Rheumatol       Date:  1987-12       Impact factor: 2.980

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.